After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. The stock was recently discussed on Yahoo Finance as it revealed that bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Bluebird bio Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Bluebird bio Inc is $229.36M. A total of 3.68 million shares were traded on the day, compared to an average of 9.02M shares.
In the most recent transaction, Obenshain Andrew sold 6,095 shares of BLUE for 1.53 per share on Mar 04 ’24. After the transaction, the President and CEO now owns 279,998 company shares. In a previous transaction on Mar 04 ’24, Klima Thomas J sold 4,573 shares at 1.53 per share. BLUE shares that the insider owns now total 124,840.
Among the insiders who sold shares, Colvin Richard A disposed of 6,770 shares on Mar 01 ’24 at a per-share price of $1.53. This resulted in the Chief Medical Officer holding 118,368 shares of BLUE after the transaction. In another insider transaction, Vittiglio Joseph sold 5,217 shares at $0.90 per share on Feb 05 ’24. Company shares held by the Chief Business & Legal Officer now total 44,783.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, BLUE has a high of $5.53 and a low of $0.88.
As of this writing, BLUE has an earnings estimate of -$0.64 per share for the current quarter. EPS was calculated based on a consensus of 11 estimates, with a high estimate of -$0.45 per share and a lower estimate of -$0.98. The company reported an EPS of -$0.67 in the last quarter, which was 6.90% higher than expectations of -$0.72.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. BLUE’s latest balance sheet shows that the firm has $299.50M in Cash & Short Term Investments as of fiscal 2021. There were $89.58M in debt and $152.99M in liabilities at the time. Its Book Value Per Share was $2.08, while its Total Shareholder’s Equity was $374.28M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BLUE is Buy with a score of 3.54.
